It’s Their Own Fault We No Longer Default to Respect
Did This Issue Catapult Japanese Conservatives to a Landslide Win in Their Elections?
US Women's Hockey Team Clubbed the Canadians Like Baby Seals Yesterday. Oh, and...
Of Course, This GOP Senator Stabbed Us in the Back on Election Integrity
Why This Girl Wrestler Had Shock and Horror All Over Her Face in...
Bill Maher Reveals Why He Got the COVID Vaccine...and He's Rather Annoyed About...
Police Released Person of Interest Detained in Guthrie Disappearance. Here's What We Know.
Report: The FAA Just Closed El Paso Airspace for Ten Days Over 'Security...
Technological Sweet Spot
Public Opinion: A Tyrant Against Hard Decisions
Peggy Noonan Loses Her Noodle Over Washington Post Layoffs
Misconduct Rampant: America’s Leaders Increasingly Prioritize Agendas Over Fairness, Laws
2026 Olympics: Let’s Talk About Crotch Scandals
The Washington Post Is Paying the Bill for Free Speech
Republicans Siding With Big Banks in Stablecoin Fight Could Tank Trump’s Affordability Age...
Tipsheet

What's Wrong with the Country? Ask Future Congressmen Wohl and Fruchter, LLP

Welcome to Ransom's Stocks in the News where the headline meets the trendline.

Stocks in the News is produced by John Ransom in conjunction with Ransom Notes Radio

Advertisement

.Stock Number One: Ariad Pharma (SYMBOL: ARIA)

And the headline says: Ariad Pharma shares plunge 57%; patient enrollment in clinical studies of Iclusig is being paused- Briefing.com

“The Company is implementing the following actions in its Iclusig clinical development program,” writes Briefing.com. “Patient enrollment in all clinical studies of Iclusig is being paused, and subject to agreement with the FDA, will be resumed with anticipated changes in dose and other modifications. In concert with this action, the FDA placed a partial clinical hold on all new patient enrollment in clinical trials of Iclusig. Patients who are currently receiving Iclusig in clinical trials will continue on therapy.”

What clinical trials give, clinical trials take away.

Ariad Pharma has enjoyed a 52-week high around $25.40. But the stock is been dropping all year on poor clinical results.

The company closed at $17.14 yesterday is now trading today at $5.14

And right on time this from Business Wire: ARIA SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Announces Investigation of Ariad Pharmaceuticals Inc.

If you want to know what’s wrong with the country the law firm of Wohl and Fruchter LLP is exhibit number 1.

Because one day, after they are done screwing with Ariad, either Wohl or Fruchter will end up in Congress.

Advertisement

Our Ransom Notes Trendline says: Avoid Ariad Pharma.

ARIA Chart

ARIA data by YCharts

Stock number two: Baidu, Inc. (SYMBOL: BIDU)

And the headline says: China Internet Rally Will Continue On Earnings Surprises, Says JPM- Barrons

“Chinese Internet stocks within J.P. Morgan‘s coverage have on average risen 122% this year,” writes Barrons. “On a P/E and PEG (P/E versus growth) multiple basis, the sector is now trading higher than its historical range. Investors are understandably nervous that the rally would soon deflate.”

Not so says JPM.

The company thinks that Baidu’s earnings might surprise people, even if P/E multiples don’t expand.

The companies currently trading about 30 times trailing 12 months earnings, which sounds to me more like a football score then a price-earnings ratio. The stock is trading at 13 times- yes that’s 13 times- sales.

We think BAIDU is BAD 4 U.

Our Ransom Note Trendline says: Sell Baidu

BIDU Chart

BIDU data by YCharts

Stock Number Three: Alcoa Inc (SYMBOL: AA)

And the headline says: Thoughts On The First Big Q3 Earnings Number- Seeking Alpha

“The aluminum/alumina company Alcoa's (AA) Q3 EPS came in at 2 cents per share,” writes Seeking Alpha. “However back out various ‘special items’ and this figure rises to 11 cents, which was better than the 6 cents hoped for. So a ‘beat’ in earning parlance terms. Of course, the ‘earnings shuffle’ means that expectations were reduced before the numbers were released.”

Advertisement

The number is good because Alcoa is thought to be a bell weather stock helping determine the general trend of the economy both at home and globally.

That’s said, the chart on Alcoa is definitely bearish with the company trading below both its 50-day and 200-day moving averages.

Earnings have shrunk substantially over the last five years for the company on ppor global conditions. And while that’s expected to change shortly, this is a stock that’s going nowhere real fast.

It’s trading about 20 times its forward price earnings, with the dividend of about 1 ½%.

It is after all only aluminum. How exciting can that be?

Our Ransom Note Trendline says: Avoid Alcoa, Inc.

AA Chart

AA data by YCharts

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos